Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More
Monday January 28, 2019 0 comments
Clovis Oncology announces positive hearing for Rubraca in Europe
BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More
Wednesday December 5, 2018 0 comments
Clovis Oncology announces second patent for Rucaparib high dose
BOULDER -- Clovis Oncology , Inc. (NASDAQ:CLVS) today announced the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating... Read More
Tuesday November 20, 2018 0 comments
Clovis Oncology receives Breakthrough Therapy designation for Rubraca
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More
Tuesday October 2, 2018 0 comments
Clovis Oncology announces first patient enrolled in cancer trial
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis Rubraca (rucaparib), a... Read More
Wednesday August 8, 2018 0 comments
Clovis Oncology receives European validation for Rubraca cancer drug
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ... Read More
Thursday July 5, 2018 0 comments
Clovis Oncology announces European authorization of rucaparib for ovarian cancer care
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More
Tuesday May 29, 2018 0 comments
Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment
BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) announced the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with... Read More
Monday April 9, 2018 0 comments
- 1
- 2
IN Sponsors
Browse
.jpg)
Entrepreneurial by Nature
